Kate Evans serves as the Executive Director of Quality at Eli Lilly and Company, where she plays a pivotal role in overseeing the quality assurance and compliance of a cutting-edge greenfield parenteral formulation and filling site. With a strong foundation in Lean Manufacturing and Six...
Kate Evans serves as the Executive Director of Quality at Eli Lilly and Company, where she plays a pivotal role in overseeing the quality assurance and compliance of a cutting-edge greenfield parenteral formulation and filling site. With a strong foundation in Lean Manufacturing and Six Sigma methodologies, Kate is adept at driving operational excellence while ensuring that all processes meet stringent regulatory standards. Her expertise in project management and CAPA (Corrective and Preventive Action) systems allows her to lead complex initiatives that enhance product quality and safety, ultimately benefiting patients who rely on Eli Lilly's innovative therapies.
In her current role, Kate is spearheading key projects focused on the implementation of robust quality systems that support the site’s manufacturing capabilities, including inspection, device assembly, and packaging. Her data-driven approach enables her to identify areas for improvement and streamline operations, fostering a culture of continuous improvement among her teams. Known for her exceptional team leadership skills, Kate has a unique ability to cultivate trust and confidence within her workforce, even in high-pressure situations. By effectively reading dynamics and leveraging her strong interpersonal skills, she inspires her teams to embrace challenges and collaborate towards common goals.
Kate's commitment to quality and her strategic vision have positioned her as an influential resource within Eli Lilly. Her contributions not only enhance the site’s operational performance but also align with the company’s mission to deliver high-quality medicines to patients around the globe. Through her leadership, Kate continues to drive innovation and excellence in the pharmaceutical manufacturing landscape.
